Regulation of DNA repair gene expression in human cancer cell lines

Journal of Cellular Biochemistry

Volumn 97, Issue 5, 2006, Pages 1121-1136

  McGurk, Claire J ^a   Cummings, Michele ^a   Köberle, Beate ^b   Hartley, John A ^c   Oliver, R Timothy ^d   Masters, John R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

ERCC1; Nucleotide excision repair; Real time PCR; Testicular cancer; XPA; XPF

Indexed keywords

CISPLATIN; TRANSCRIPTION FACTOR;

ADVANCED CANCER; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER CELL CULTURE; DNA ADDUCT; DNA REPAIR; EXCISION REPAIR; GENE EXPRESSION REGULATION; GENETIC REGULATION; GERM CELL TUMOR; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA STABILITY; TESTIS CANCER; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; 5' UNTRANSLATED REGIONS; ALTERNATIVE SPLICING; BLOTTING, NORTHERN; CELL LINE, TUMOR; CISPLATIN; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; GENE EXPRESSION REGULATION; HUMANS; MALE; NEOPLASMS; PROMOTER REGIONS (GENETICS); PROTEIN BIOSYNTHESIS; REPRESSOR PROTEINS; RNA, MESSENGER; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION, GENETIC; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 33645242176     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20711     Document Type: Article

References (44)

1. Bedford P, Fichtinger-Schepman AM, Shellard SA, Walker MC, Masters JR, Hill BT. 1988. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 48:3019-3024.
2. Bramson J, McQuillan A, Panasci LC. 1995. DNA repair enzyme expression in chronic lymphocytic leukemia vis-à-vis nitrogen mustard drug resistance. Cancer Lett 90: 139-148.
3. Britten RA, Liu D, Tessier A, Hutchinson MJ, Murray D. 2000. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 20:453-457.
4. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K, Lee M, Liu J, Wrensch M. 2000. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9:843-847.
5. Cheng L, Sturgis EM, Eicher SA, Spitz MR, Wei Q. 2002. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 94:393-397.
6. Codegoni AM, Broggini M, Pitelli MR, Pantarotto M, Torri V, Mangioni C, D'Incalci M. 1997. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 65:130-137.
7. Dabholkar M, Bostick-Bruton F, Yu JJ, Reed E. 1992. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512-1517.
8. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. 1994. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94:703-708.
9. Dabholkar M, Vionnet JA, Parker RJ, Bostick-Bruton F, Dobbins A, Reed E. 1995. Expression of an alternatively spliced ERCC1 mRNA species, is related to reduced DNA repair efficiency in human T lymphocytes. Oncol Rep 2: 209-214.
10. Damia G, Guidi G, D'Incalci M. 1998. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. Eur J Cancer 34:1783-1788.
11. Einhorn LH. 2002. Curing metastatic testicular cancer. Proc Natl Cancer Inst 99:4592-4595.
12. Ferry KV, Hamilton TC, Johnson SW. 2000. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: Role of ERCC1-XPF. Biochem Pharmacol 60: 1305-1313.
13. Fink F, Seeger W, Ermert L, Hanze J, Stahl U, Grimminger F, Kummer W, Bohle RM. 1998. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 4: 1329-1333.
14. Fu L, Benchimol S. 1997. Participation of the human p53 3′UTR in translational repression and activation following γ-irradiation. EMBO J 16:4117-4125.
15. Fujishima H, Nakano S, Masumoto N, Esaki T, Tatsumoto T, Kondo T, Niho Y. 1997: Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line. Oncol Res 9:167-172.
16. Galm O, Fabry U, Efferth T, Osieka R. 2002. Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression. Cancer Lett 187:143-151.
17. Geleziunas R, McQuillan A, Malapetsa A, Hutchinson M, Kopriva D, Wainberg MA, Hiscott J, Bramson J, Panasci L. 1991. Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J Natl Cancer Inst 83:557-564.
18. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala SL. 2001. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharamcol 48: 398-406.
19. Juhasz A, Franzel P, Cheng C, Rivera H, Vishwanath R, Chiu A, Margolin K, Yen Y, Newman EM, Synold T, Wilczynski S, Lenz HJ, Gandara D, Albain KS, Longmate J, Doroshow JH. 2003. Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. J Clin Lab Anal 17:184-194.
20. Köberle B, Payne J, Grimaldi K, Hartley JA, Masters JRW. 1996. DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem Pharmacol 52:1729-1734.
21. Köberle B, Grimaldi KA, Sunters A, Hartley JA, Kellend LR, Masters JRW. 1997. DNA repair capacity and cisplatin sensitivity of human testis tumor cells. Int J Cancer 70:551-555.
22. Köberle B, Masters JRW, Hartley JA, Wood RD. 1999. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumors. Current Biol 9:273-276.
23. Layher SK, Cleaver JE. 1997. Quantification of XPA gene expression levels in human and mouse cell lines by competitive RT-PCR. Mutat Res 383:9-19.
24. Leatherman JL, Jongens TA. 2003. Transcriptional silencing and translational control: Key features of early germline development. BioEssays 25:326-335.
25. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E. 2000. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20:645-652.
26. Lord RVN, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez PH, Gumerlock PH, Taron M, Sanchez JJ, Danenberg KD, Danenberg PV, Rosell R. 2002. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291.
27. Mazumder B, Seshadri V, Fox PL. 2003. Translational control by the 3′-UTR: The ends specify the means. Trends Biochem Sci 28:91-98.
28. Meijer HA, Thomas AAM. 2002. Control of eukaryotic protein synthesis by upstream open reading frames in the 5′-untranslated region of an mRNA. Biochem J 367:1-11.
29. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L. 1998. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16:309-316.
30. Reed E. 1998. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24:331-344.
31. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ. 2001. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298-4304.
32. Spicher A, Guicherit OM, Duret L, Aslanian A, Sanjines EM, Denko NC, Giaccia AJ, Blau HM. 1998. Highly conserved RNA sequences that are sensors of environmental stress. Mol Cell Biol 18:7371-7382.
33. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q. 2002. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 128:1084-1089.
34. van Duin M, de Wit J, Odijk H, Westerveld A, Yasui A, Koken HM, Hoeijmakers JH, Bootsma D. 1986. Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell 44:913-923.
35. Vogel U, Dybdahl M, Frentz G, Nexo BA. 2000. DNA repair capacity: Inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res 461:197-210.
36. Walker MC, Parris CN, Masters JR. 1987. Differential sensitivities of human testicular and bladder tumor cell lines to chemotherapeutic drugs. J Natl Cancer Inst 79: 213-216.
37. Welsh C, Day R, McGurk C, Masters JRW, Wood RD, Köberle B. 2004. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 110:352-361.
38. Wilson MD, Ruttan CC, Koop BF, Glickman BW. 2001. ERCC1: A comparative genomic perspective. Environ Mol Mutagenesis 38:209-215.
39. Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Aloyz R, Panasci LC. 2002. DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 13:511-519.
40. Yen L, Woo A, Christopoulopoulos G, Batist G, Panasci L, Roy R, Mitra S, Alaoui-Jamali MA. 1995. Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bifunctional alkylating agents. Mutat Res 337:179-189.
41. Yu JJ, Mu C, Dabholkar M, Guo Y, Bostick-Bruton F, Reed E. 1998. Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. Int J Mol Med 1:617-620.
42. Yu JJ, Thornton K, Guo Y, Kotz H, Reed E. 2001. An ERCC1 splicing variant involving the 5′-UTR of the mRNA may have a transcriptional modulatory function. Oncogene 20:7694-7698.
43. Zhao R, Rabo YB, Egyhazi S, Andersson A, Edgren MR, Linder S, Hansson J. 1995. Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line. Anticancer Drugs 6:657-668.
44. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC. 2004. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10:4939-4943.